Stock Events

Stock Events

Lonza Group 

C$9.56
167
+C$0+0% Wednesday 18:29

Statistics

Day High
9.6
Day Low
9.56
52W High
10.1
52W Low
9.5
Volume
1,600
Avg. Volume
25
Mkt Cap
0
P/E Ratio
-
Dividend Yield
0.24%
Dividend
0.02

Upcoming

14
MAY
Dividend Ex
Estimated
 
27
MAY
Dividend Payment
Estimated
 
14
MAY 27
Dividend Ex
Estimated
 
27
MAY 27
Dividend Payment
Estimated
 
15
MAY 28
Dividend Ex
Estimated
 

Dividends

0.24%Dividend Yield
May 25
C$0.02
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

22JulExpected
Q4 2024
Q2 2025
Q4 2025
Next
12.1
13.48
14.85
16.22
Expected EPS
13.737467591406
Actual EPS
N/A

Financials

9.65%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
10.22BRevenue
986.6MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow LON.NEO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Thermo Fisher Scientific
TMO
Mkt Cap184.37B
Thermo Fisher Scientific offers similar biotechnology and pharmaceutical services, including contract manufacturing and development services, competing directly with Lonza's core business.
Danaher
DHR
Mkt Cap134.19B
Danaher Corporation, through its Life Sciences segment, competes in the bioprocessing space, offering products and services that overlap with Lonza's offerings in pharmaceutical development and manufacturing.
Charles River Laboratories International
CRL
Mkt Cap8.67B
Charles River Laboratories provides a range of preclinical and clinical laboratory services for the pharmaceutical, medical device, and biotechnology industries, competing with Lonza in contract development and manufacturing organization (CDMO) services.
IQVIA
IQV
Mkt Cap28.4B
IQVIA offers extensive clinical research services, including biopharmaceutical development, which competes with Lonza's services in drug development and manufacturing.
West Pharmaceutical Services
WST
Mkt Cap18.49B
West Pharmaceutical Services specializes in designing and manufacturing containment and delivery systems for injectable drugs and healthcare products, competing with Lonza in the pharmaceutical and biotech supply chain.
Bio-Rad Laboratories
BIO
Mkt Cap7.54B
Bio-Rad Laboratories offers products and services in life science research and clinical diagnostics, competing with Lonza in the provision of specialized instruments and reagents for the pharmaceutical industry.

About

Lonza Group AG, together with its subsidiaries, operates as a contract development and manufacturing organization for pharma and biotech companies in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Integrated Biologics; Advanced Synthesis; and Specialized Modalities segments. The Integrated Biologics segment offers CDMO biologics services from clinical development, drug substance, and drug product manufacturing; and operates mammalian and drug product platforms. Its Advanced Synthesis segment manufactures antibody-drug conjugates (ADCs) and other bioconjugates, small molecules, and highly potent active pharmaceutical ingredients; and operates small molecules and bioconjugates platforms. The Specialized Modalities segment operates various technologies, such as spanning cell & gene, microbial, bioscience, and mRNA. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.
Show more...
CEO
Dr. Wolfgang Wienand Ph.D.
Employees
20000
Country
Switzerland
ISIN
CA5429191052

Listings

MI
IT
1LONN.MI
MX
MX
LONNN.MX
F
DE
LO31.F
NEO
CA
LON.NEO

0 Comments

Share your thoughts

FAQ

What is Lonza Group stock price today?▼
The current price of LON.NEO is C$9.56 CAD — it has increased by +0% in the past 24 hours. Watch Lonza Group stock price performance more closely on the chart.
What is Lonza Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Lonza Group stocks are traded under the ticker LON.NEO.
When is the next Lonza Group earnings date?▼
Lonza Group is going to release the next earnings report on July 22, 2026.
What were Lonza Group earnings last quarter?▼
LON.NEO earnings for the last quarter are 14.72 CAD per share, whereas the estimation was 16.22 CAD resulting in a -9.23% surprise. The estimated earnings for the next quarter are N/A CAD per share.
What is Lonza Group revenue for the last year?▼
Lonza Group revenue for the last year amounts to 10.22B CAD.
What is Lonza Group net income for the last year?▼
LON.NEO net income for the last year is 986.6M CAD.
Does Lonza Group pay dividends?▼
Yes, LON.NEO dividends are paid annual. The last dividend per share was 0.02 CAD. As of today, Dividend Yield (FWD)% is 0.24%.
How many employees does Lonza Group have?▼
As of April 14, 2026, the company has 20,000 employees.
In which sector is Lonza Group located?▼
Lonza Group operates in the Health & Wellness sector.
When did Lonza Group complete a stock split?▼
Lonza Group has not had any recent stock splits.
Where is Lonza Group headquartered?▼
Lonza Group is headquartered in Basel, Switzerland.